Balaji Amines Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹456Cr
- +27.4% YoY
- +15.4% QoQ
- Net profit
- ₹78Cr
- +110.8% YoY
- +20% QoQ
- Margin
- 25%
- +10 pp YoY
- +1 pp QoQ
Guidance rank: #26 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
Based on Balaji Amines Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q1 FY27: Rs. 456 Cr (vs Rs. 358 Cr in Q1 FY26), a 27% year-on-year increase. EBITDA for Q1 FY27: Rs. 121 Cr, up 91.51% YoY from Rs. 63 Cr in Q1 FY26.
From Balaji Amines Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q1 FY27: Rs. 456 Cr (vs Rs. 358 Cr in Q1 FY26), a 27% year-on-year increase.
- Total Revenue for Q1 FY27: Rs. 461 Cr (vs Rs. 367 Cr in Q1 FY26), up 25.7% year-on-year.
- Volume Growth Outlook: FY27 volume growth guided at 10-15%, with a medium-term growth target of 20-30%.
2 more points from Balaji Amines Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- ₹1000 Cr+ expansion cycle nearing completion on consolidated basis (Page 14)
- Capital work-in-progress of Rs. 401.06 Cr at BSCL for:
- Greenfield expansion to manufacture HCN, NaCN, EDTA, EDTA-Na, and other advanced chemicals
- Brownfield expansions for EDA-based chemical production (Page 28)
- Upcoming projects:
- HCN, Sodium Cyanide, EDTA & EDTA-2Na greenfield project, commissioning targeted by end FY27 (Page 13)
- EDA derivatives project (DETA, TETA, PIP, AEEA & AEP), commissioning targeted during FY27 (Page 13)
- NMM (N-Methyl Morpholine) plant expansion: 5,000 TPA proposed, expected commissioning by FY27 (Pages 14, 12)
- Acetonitrile (ACN) expansion: 9,000 TPA proposed additional capacity, commissioning expected in FY27 (Pages 14, 12)
- DME plant: 100,000 TPA, India's first commercial-scale, successfully commissioned in Q1 FY27 (Page 12)
2 more points from Balaji Amines Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Balaji Amines Ltd — Quarterly revenue & net profit
Balaji Amines Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 456 | 358 | +27.4% | 395 | +15.4% |
| Operating profit (EBITDA) | 116 | 55 | +110.9% | 94 | +23.4% |
| Operating margin | 25% | 15% | +10 pp | 24% | +1 pp |
| Profit before tax | 106 | 49 | +116.3% | 86 | +23.3% |
| Net profit (PAT) | 78 | 37 | +110.8% | 65 | +20% |
| EPS (₹) | 23.13 | 11.73 | +97.2% | 19.51 | +18.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹468 Cr, net profit ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaji Amines's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Alufluoride (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
- POCL Enterprises (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
- Devson Catalyst (Q1 FY27)
FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee
- Ambani Orgochem (Q1 FY27)
Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Balaji Amines Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Balaji Amines Ltd Q1 FY27 results?
Revenue from Operations for Q1 FY27: Rs. 456 Cr (vs Rs. 358 Cr in Q1 FY26), a 27% year-on-year increase. EBITDA for Q1 FY27: Rs. 121 Cr, up 91.51% YoY from Rs. 63 Cr in Q1 FY26.
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
₹1000 Cr+ expansion cycle nearing completion on consolidated basis (Page 14)
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
